Eckstein, a venture partner and entrepreneur-in-residence at Germany-based venture capital firm TVM Capital, will report to GSK's research and development chairman Moncef Slaoui and be based in Boston, US.
Jens Eckstein (Pictured) will become president of SR One, UK-based drugs company GlaxoSmithKline’s (GSK) corporate venturing unit, at the start of next month.
He replaces Christoph Westphal, who will be leaving at the end of the year to focus on external business interests, including the Longwood Founders Fund, in which GSK is an investor.
Eckstein, a venture partner and entrepreneur-in-residence at Germany-based venture capital firm TVM Capital, will report to GSK’s research and development chairman Moncef Slaoui and…
